Clinical Trial Update: Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants [Phase 1]

View source ↗

Summary

Phase 1 clinical trial comparing pharmacokinetics, safety, tolerability, and immunogenicity of CKD-704, a risankizumab biosimilar, with EU- and US-approved risa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• CKD-704 (risankizumab)
• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Psoriasis | Phase 1 | Status: RECRUITING